BIOLOGY OF SIV IN THE AFRICAN GREEN MONKEY

描述：(改编自申请人摘要)。本RO_3是一种 申请到福格蒂国际艾滋病国际研究中心 和培训计划。这项合作研究的目标是 加州区域灵长类研究中心(CRPRC)和 肯尼亚灵长类动物研究(IPR)将定义猿猴的生物学 免疫缺陷病毒(SIVagm)在自然宿主非洲绿猴中的感染 (AGM)、海鞘天牛Cercopethecus atheiops.值得注意的是，股东周年大会没有 在艾滋病和SIV研究中大量使用。尽管有大量的人 野生和圈养的非洲绿猴(AGM)的数量持续增加 感染了SIVagm的人没有表现出猴艾滋病的临床症状， 与感染SIVagm的亚洲猕猴不同。这一观察导致了 认为SIVagm和它的自然宿主共同进化成了 非致病关系。因此，这项研究将寻求澄清 SIVagm在年度股东大会上的生物学通过定义(A)SIVagm的生物学 来自野生的自然感染的动植物，(B)西瓦姆的生物学 实验感染圈养成虫，(C)病毒途径的作用 SIVagm致病机理的接种及(D)SIVagm生物学研究 免疫不成熟的宿主，AGM新生儿。作者认为， 股东大会为寻求这些问题的答案提供了一个极好的模式，因为 (I)超过三分之一的野生和圈养动植物检疫动物感染SIV(Ii) AGM-感染SIVagm是非致病性的；和(Iii)大量的AGM 可用于拟议的研究。因此，这项研究建议使用 自然感染的股东大会、静脉或粘膜感染的成人股东大会和 新生儿AGMS检测和确定(A)抗SIV细胞毒性T细胞 (B)外周血中的病毒载量和 血浆，(C)SIVagm在组织和器官中的分布。

DESCRIPTION: (Adapted from Applicant's Abstract). This RO3 is an application to the Fogarty International Center AIDS International Research and Training Program. The objective of this collaborative study between California Regional Primate Research Center (CRPRC) and the Institute of Primate Research (IPR) in Kenya is to define the biology of simian immunodeficiency virus (SIVagm) in a natural host, the African green monkey (AGM), Cercopethecus aethiops. It is noteworthy that the AGMs have not been heavily used in AIDS and SIV research. Despite the fact that large numbers of African green monkeys (AGMs) in the wild and captivity are persistently infected with SIVagm, they do not display clinical signs of simian AIDS, unlike Asian macaques infected with SIVagm. This observation has led to suggestions that SIVagm and its natural host have co-evolved into a nonpathogenic relationship. This study will therefore seek to clarify the biology of SIVagm in the AGM by defining (a) the biology of SIVagm in naturally infected AGMs from the wild, (b) the biology of SIVagm in experimentally infected captive AGMs, (c) the role of routes of virus inoculation on SIVagm pathogenesis and (d) the biology of SIVagm on immunologically immature host, the AGM newborn. The authors suggest that AGMs provide an excellent model to seek answers to these questions, because (i) over one third of wild and captive AGMs are SIV-infected (ii) AGM-infection with SIVagm is nonpathogenic and (iii) large numbers of AGMs are available for the proposed study. This study therefore proposes to use naturally infected AGMs, intravenously or mucosally infected adult AGMs and newborn AGMs to examine and define (a) anti-SIV cytotoxic T-cell lympocyte (CTL) and antibody responses, (b) viral burden in the peripheral blood and plasma, (c) the SIVagm distribution in tissues and organs.